COMMUNIQUÉS West-GlobeNewswire

Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections

04/01/2018 - 14:00

SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX ), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that a new compendium of papers [...]

Celsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian Cancer

04/01/2018 - 14:00

GEN-1 to Enter the Clinic in Mid-2018 Following a Phase IB Trial Which Demonstrated 100% Disease Control, 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated Compelling [...]

Stemline Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

04/01/2018 - 14:00

NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML ), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers announced today that Ivan [...]

IntelGenx To Present at Biotech Showcase(TM) 2018

04/01/2018 - 14:00

SAINT-LAURENT, Quebec, Jan. 04, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx") today announced that its President and Chief Executive Officer, Dr. Horst Zerbe, is [...]

Onconova Therapeutics Announces Cooperative Research and Development Agreement for Rigosertib with the National Cancer Institute

04/01/2018 - 14:00

Agreement related to study of rigosertib in pediatric RASopathies Clinical trial in pediatric patients to be conducted by the National Cancer Institute RASopathies are orphan diseases believed to be caused by molecular [...]

Dynavax to Present at J.P. Morgan 36th Annual Healthcare Conference

04/01/2018 - 12:00

BERKELEY, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX ) announced today that Eddie Gray, Dynavax’s chief executive officer, will present at the J.P. Morgan 36th Annual [...]

OraSure Technologies Announces Management Succession Plan

04/01/2018 - 12:00

BETHLEHEM, Pa., Jan. 04, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR ), a leader in point of care diagnostic tests and specimen collection devices, today announced a succession plan for its [...]

Orion to renew operating model of its laboratories

04/01/2018 - 10:16

ORION CORPORATION PRESS RELEASE 4 JANUARY 2018 at 11.15 Orion to renew operating model of its laboratories Orion improves the competitiveness of its laboratory operations by renewing their operating model in Finland. As [...]

BioNTech Secures USD 270 Million in Series A Financing

04/01/2018 - 08:30

MAINZ, Germany, Jan. 04, 2018 (GLOBE NEWSWIRE) -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced it has completed a USD 270 million Series A round [...]

OSE Immunotherapeutics to present at Biotech Showcase™ 2018 Conference

04/01/2018 - 08:00

During JP Morgan Healthcare Conference San Francisco, January 8-10, 2018 NANTES, France, Jan. 04, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN:FR0012127173) (Mnémo:OSE), today announced that Dominique [...]

ASLAN Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

04/01/2018 - 08:00

SINGAPORE, Jan. 04, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the [...]

Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)

04/01/2018 - 07:15

Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of 85%[1] Promacta is [...]

NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT JANUARY 1, 2018

04/01/2018 - 07:01

NUMBER OF SHARES AND VOTING RIGHTS OF Innate Pharma AS AT January 1, 2018 Marseille, France, January 4, 2018, 7:00 AM CET Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of [...]

NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 1ER JANVIER 2018

04/01/2018 - 07:01

nouveau NOMBRE D'ACTIONS ET DE DROITS DE VOTE d'InnatE Pharma AU 1 er janvier 2018 Marseille, le 4 janvier 2018, 7h00 CET Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l' [...]

ABLYNX TO PRESENT AT THE 36th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

04/01/2018 - 07:01

GHENT, Belgium, 4 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday 8 January 2018 at 09:30 a.m. Pacific [...]

Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients

04/01/2018 - 07:01

Oslo, Norway, 4 January 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces immune activation data in the first four patients [...]

AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY

04/01/2018 - 06:59

Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney Health Alliance [...]

VELTASSA® APPROVED FOR MARKETING IN SWITZERLAND FOR THE TREATMENT OF HYPERKALAEMIA

04/01/2018 - 06:54

Klicken Sie hier für Deutsch Veuillez cliquer ici pour français SWISSMEDIC HAS APPROVED PATIROMER TO BE MARKETED IN SWITZERLAND AS VELTASSA ® FOR THE TREATMENT OF HYPERKALAEMIA (ELEVATED SERUM POTASSIUM LEVELS) IN [...]

Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock

04/01/2018 - 04:55

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA ), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, [...]